MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. today announced positive topline data from the completed Part A safety lead-in of the Company’s THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung... | April 11, 2023
United States Mihail Obrocea Biotechnology Inc European Union Non Small Cell Lung Cancer Medical Officer Mihail Obrocea
Source: marketscreener.com